Skip to main content. Skip to left menu.
  Change Text Size -+
Powerful BP Efficacy For Your Hypertension Patients

References:

  1. Chobanian AV, Bakris GL, Black HR, et al., for the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
  2. Ong KL, Cheung B, Man YB, Lau CP, Lam K. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
  3. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control — continuing disparities in adults. United States, 2005-2006. NCHS data brief no 3. Hyattsville, MD: National Center for Health Statistics, 2008.
  4. American Heart Association. Heart Disease and Stroke Statistics — 2008 Update. Dallas, Texas: American Heart Association; 2008. Available at: http://www.americanheart.org/downloadable/heart/120078608862HS_Stats%202008. final.pdf. Accessed August 18, 2008.
  5. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health. 2006;27:465-490.
  6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
  7. Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol. 1998;82:9R-14R.
  8. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension.1997;29:641-650.
  9. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
  10. Kusek JW, Lee JY, Smith DE, et al, for the AASK Pilot Study Investigators. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American study of kidney disease and hypertension (AASK) pilot study. Control Clin Trials. 1996;16(suppl 4):40S-46S.
  11. Lewis EJ, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
  12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
  13. Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998;11:462-470.
  14. Data on file, Bristol-Myers Squibb, AVAL001.
  15. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combinations of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exp Hypertens. 1999;21:1373-1396.
  16. Neutel JM, Germino FW, Smith D. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst. 2005;6:84-89.
  17. Neutel JM, Saunders E, Bakris GL, et al., and the INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens. 2005;7:578-586.
  18. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E, for the Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998;11:445-453.
  19. Oparil S, Guthrie R, Lewin AJ, et al, on behalf of the Irbesartan/Losartan Study Investigators. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther. 1998;20:398-409.
  20. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12:797-805.
  21. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens. 2006;8:850-857.
  22. Data on file AVAL004, Bristol-Myers Squibb Company, Princeton, NJ.
  23. Neutel JM, Franklin SS, Lapuerta P, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2007 Oct 11; [Epub ahead of print].
  24. Data on file AVAL003, Bristol-Myers Squibb Company, Princeton, NJ.
  25. Data on file, Bristol-Myers Squibb, AVAP002.
  26. Kopyt NP. Slowing progression along the renal disease continuum. JAOA. 2005;1005:207-215.
  27. American Diabetes Association. Position statement: standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S12-S54.
  28. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S1-S180.


WARNING: USE IN PREGNANCY
When pregnancy is detected, discontinue AVAPRO or AVALIDE as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. [See Warnings and Precautions: Fetal/Neonatal Morbidity and Mortality in the full Prescribing Information.]


Please see Indications and Important Safety Information.

 

Bristol-Myers Squibb Sanofi-Synthelabo Partnership
© 2008 Bristol-Myers Squibb Sanofi-Synthelabo Partnership 446US07WA27502 08/08 Last updated: December 2008